TORONTO, ON / ACCESSWIRE / May 20, 2015 / Silver Shield Resources (TSXV: SSR.H) (“Silver Shield” or the “Corporation”) is pleased to announce that the common shares of the Corporation have been approved for reinstatement of trading by the TSX Venture Exchange and that the common shares will resume trading on the NEX Board on Thursday May 21st, 2015.

The Corporation would also like to announce that it has entered into a secondary loan agreement with BlackBirch Capital for the amount of Twenty-Five Thousand Dollars (“$25,000.00”) CDN. The loan bears an interest rate of 24% per annum and the Corporation – pending approval by the TSX Venture Exchange – will issue BlackBirch Capital Twenty-Five Thousand (“25,000”) common share purchase warrants. Repayment of the loan is due within six months from the commencement date however the lender has the option to extend the repayment date from six months to one year. Each share purchase warrant shall allow the holder to acquire one common share of the Corporation at a price of $0.10 per share. The warrants shall expire 12 months from the date of issuance. BlackBirch Capital has also extended the repayment term of the Loan it granted Silver Shield Resources in November of 2014 from six months to one year.

The Corporation would also like to inform all of its shareholders that the Corporation held its AGM on April 30^th 2015. All resolutions passed with 18,648,138 votes being cast or 22.58% of the 82,570,350 outstanding. 18,638,138 votes were cast in favor of the resolutions, 10,000 votes were not voted and 0 votes were cast against the resolutions.

About Silver Shield Resources

Silver Shield Resources is determined to become a world class silver producing company. The Corporation continues to source both debt and equity financing to move the Corporations quality projects to first stage production. For more information please visit the corporate website at www.silvershieldresources.net.

For further information please contact:

Mr. Frank Kordy
Interim CEO
Silver Shield Resources Corp.
T: (647) 466-4037
E: frank.kordy@silvershieldresources.net

Forward-Looking Statements

Information set forth in this news release may involve forward-looking statements under applicable securities laws. The forward-looking statements contained herein are expressly qualified in their entirety by this cautionary statement. The forward-looking statements included in this document are made as of the date of this document and the Corporation disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities legislation. Although Management believes that the expectations represented in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Silver Shield Resources 

ReleaseID: 429085

COVINGTON, LA / ACCESSWIRE / May 20, 2015 / Supurva Healthcare Group, Inc. (also known as Lighthouse Petroleum, Inc.) (“Supurva”) (PINKSHEETS:LHPT), today announces it has entered into an exclusive licensing agreement with MelMedtronics, Inc. (“MelMedtronics”), a revolutionary medical device company specializing in disorders of hearing and tinnitus. Under the licensing agreement, Supurva is granted, effective immediately, exclusive rights to sell their proprietary hearing devices to customers in the Greater Houston Metropolitan Area. The audiology sector is expected to have very strong growth in the next ten years as the baby boomer generation continues to age.

MelMedtronics currently has several audiology products (one device, The Inhibitor(TM) and eight iPad applications, iA Audiometers(TM) (8 models), Tinnitus Adaptation Program (TAP(TM) ) and a new generation of treatment devices; Tinnitus Neuromodulation Treatment (TNT(R)), iA-PSAD (Personal Sound Amplification Device) and iA-HA (hearing aid) are also in development. The company’s iA-TEP(TM) application and iA Audiometers(TM) applications are iOS based and are used by Audiologists, ENT’s, Hearing Instrument Specialists, Primary Care Physicians, Pediatricians and Public Schools to evaluate their patients who have tinnitus (CPT-92625) and/or hearing loss (CPT-92577).

MelMedrotronics has also developed a Tele-Audiology system that uses iOS devices (iPads and/or iPhones) to evaluate patients anywhere in the world, which will greatly reduce the cost of evaluation and treatment for hearing impaired individuals world-wide.

Gerard Danos, Chairman and CEO of Supurva stated, “Management believes this new venture in audiology has even greater opportunity in the long term care sector than the company’s expanding dental business and will soon become one of the cornerstone businesses of Supurva Healthcare Group. In addition, the entry into this sector produces obvious synergies between our other businesses as most of our existing clients are also candidates for MelMedtrontonics’ audiology products.”

About Supurva Healthcare Group, Inc. AKA Lighthouse Petroleum, Inc.

Supurva Healthcare Group, Inc., a Delaware Corporation, is a healthcare holdings company based in Covington, LA. Supurva, through its wholly own subsidiary On-Site Solutions, LLC, provides on-site healthcare for acute, subacute, and nursing facility residents / patients; specializing in dentistry, podiatry, optometry, and wound care. On-Site Solutions, LLC currently has arrangements with 13 long term care facilities in Texas in its growing portfolio totaling roughly 1200 beds.

Forward Looking Statement

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may,” “future,” “plan” or “planned,” “will” or “should,” “expected,” “anticipates,” “draft,” “eventually” or “projected.” You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks. Supurva Healthcare Group, LLC is a holdings company with limited experience in the healthcare industry. At the time of this release Supurva Healthcare Group, LLC lacks the financial capabilities to meet its financial obligations and its management expects to dilute the company’s shares to raise the necessary operating capital. Based upon industry standards Supurva would be considered highly speculative and lacks any competitive advantage over its competition. Additional risks you should consider are that this list is limited and additional risk not mentioned may apply: failure to meet Supurva’s financial and contractual obligations, Supurva’s managerial errors made based upon the Company’s limited experience and knowledge of the industry, commodity risk, acts of God and regulatory risk. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements.

Contact:
Gerard Danos, Chairman & CEO
gdanos@lighthousepetroleum.com
985-237-3701

SOURCE: Lighthouse Petroleum, Inc.

ReleaseID: 429103

HOUSTON, TX / ACCESSWIRE / May 20, 2015 / Hydrogen Future Corp. (PINKSHEETS: HFCO) announced today that it has signed a Letter of Intent to acquire Clinical Research Southeast, Inc. (“CRS”). CRS was formed to aggregate and operate existing clinical research organizations in the U.S. southeast.

CRS has assembled an experienced management team with significant capacity to manage company operations. It is their goal to centralize multi-site CRO’s to provide large-scale, outsourced clinical trial services to pharmaceutical, biotech, medical device companies and other research organizations.

CRS recently completed its first acquisition in its aggregation plan with the purchase of Phase One Solutions, Inc. (“Phase One”), a CRO which provides high quality phase one clinical testing services. Its 140-bed facility with dedicated staff is one of the largest in-house clinical research sites in the southeast. With an in-house lab and pharmacy, Phase One has the ability to cut costs and expedite study timelines.

HFCO believes that CRS’s management team, significant revenue and cash flow strongly favor the success of their aggregation strategy.

HFCO will seek a buyer for its wholly owned subsidiary, Hydra Fuel Cell Corp.

Safe Harbor Statement

The statements in this release that relate to the Company’s expectations with regard to the future impact on the Company’s results from new products in development are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The results anticipated by any or all of these forward-looking statements may not occur. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in the Company’s plans or expectations.

For more information about HFCO, please contact:

Frank Neukomm or Bob Farr at 281-436-6036 and leave a message.
www.hydrogenfuturecorp.com

For more information about CRS, please contact:

Conrad Huss
Chief Financial Officer, at 212-994-9873 and leave a message.

SOURCE: Hydrogen Future Corp.

ReleaseID: 429057

TORONTO, ON / ACCESSWIRE / May 20, 2015 / Wi2Wi Corporation (“Wi2Wi” or the “Company”) a leading global developer and manufacturer of wireless connectivity solutions, high precision frequency control devices, timing devices, and microwave filter devices announced today a new line of Custom Cavity Filters. The CCF Filter Series are Custom Cavity Combline (CF) Filters and offered in standard and custom packaging. The CCF Filter Series is configurable per customer’s requirements and available in frequency ranges from 0.5 to 18 GHz. Samples are available.

“The CCF filter series addresses the market demands for high performance filters in the Military, Avionics, Space, and GPS areas,” said Samuel Johnson, Director of Microwave Business Unit. “We are dedicated to provide filter solutions that meet our customer’s specifications, cost effective, and support rapid prototyping to mass production. Our focus is on providing custom solutions to service the unique requirements of our customers,” Mr. Johnson added.

“This new filter series is the newest extension of our complete product offering,” said Tom Sokol, Senior Director of North American Sales for Wi2Wi. “With our experienced engineering team and proven design process, Wi2Wi can continue to offer standard and custom RF and Microwave filter solutions to the growing market place”

“Our filter business continues to grow,” said Gregg Harvey, V.P. and General Manager. “Our new CCF product is another example of extending into new types of filters for our customers.”

About Wi2Wi Corporation

Wi2Wi is a vertically integrated global manufacturer provide connectivity solutions, Timing Devices, frequency Controllers and Microwave Filters to the global market. Wi2Wi’s miniaturized Wireless System-in-Package (SIP) connectivity Solutions are well accepted in the global market for Machine-to-Machine (M2M and Internet of Things (IOT) and portable device embedded applications worldwide. Acquisition of net operating assets of Precision Devices Inc., in November 2014 enabled Wi2Wi to expand its product offering by adding Timing Devices and frequency Controllers to its product offering. Precision Device’s, rugged, robust and reliable High end Crystals and Oscillators, Crystal Filters, RF and Microwave Filters are widely used and well recognised in the premium markets; Industrial, Avionics, Space, Medical and Defense.

Headquartered in San Jose, California, the heart of the Silicon Valley with manufacturing operations in Middleton, Wisconsin, the industrial belt of North America, Wi2Wi provides leading-edge wireless solutions, customized Timing Devices, frequency controllers and microwave filters for customer applications worldwide with substantial savings on time-to-market, cost and system-integration. Wi2Wi also leverages its technology along with tier-1 global partnerships with industry leading silicon and supply chain companies, serving a large number of Fortune-500 customers.

For further information, please contact:

Zachariah Mathews
President and Chief Executive Officer
408 416 4202
zach@wi2wi.com

Forward-Looking Statements: This news release contains certain forward-looking statements, including management’s assessment of future plans and operations, and the timing thereof, that involve substantial known and unknown risks and uncertainties, certain of which are beyond the Company’s control. Such risks and uncertainties include, without limitation, risks associated with the ability to access sufficient capital, the impact of general economic conditions in Canada, the United States and overseas, industry conditions, stock market volatility. The Company’s actual results, performance or achievements could differ materially from those expressed in, or implied by, these forward-looking statements and, accordingly, no assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what benefits, including the amount of proceeds, that the Company will derive there from. Readers are cautioned that the foregoing list of factors is not exhaustive. Additional information on these and other factors that could affect the Company’s operations and financial results are included in reports on file with Canadian securities regulatory authorities and may be accessed through the SEDAR website (www.sedar.com). Forward-looking statements are made based on management’s beliefs, estimates and opinions on the date the statements are made and the Company undertakes no obligation to update forward-looking statements and if these beliefs, estimates and opinions or other circumstances should change, except as required by applicable law. All subsequent forward-looking statements, whether written or oral, attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these cautionary statements. Furthermore, the forward-looking statements contained in this news release are made as at the date of this news release and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by applicable securities laws.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Wi2Wi Corporation

ReleaseID: 429084

NEWTOWN, PA / ACCESSWIRE / May 20, 2015 / Helius Medical Technologies (“Helius”, “HMT”, or the “Company”) announced that it has achieved full enrollment for its Multiple Sclerosis pilot clinical trial at the Montreal Neurological Institute. The trial, “Examining the efficacy of non-invasive neuromodulation in reducing symptoms of Multiple Sclerosis”, launched in February 2015, is a 14 subject, blinded feasibility study investigating Helius’ Portable Neuromodulation Stimulator (PoNS?) and physiotherapy protocol on the rehabilitation of balance and gait symptoms in subjects with Multiple Sclerosis.

Subjects enrolled in the study receive treatment with the PoNS device and concomitant physiotherapy designed to improve both balance and gait. The primary endpoint, at 14-weeks, is improvement in gait as quantified by the DGI (Dynamic Gait Index) and improvement in balance as measured by the Sensory Organization Test (SOT). The study, including data analysis, is expected to conclude in Q4 2015.

“Achieving full enrollment of this study within our forecasted timeline is a significant milestone for Helius and our research into Multiple Sclerosis,” said Helius’ CEO, Philippe Deschamps. “This pilot protocol is primarily designed to be an external validation of a previously published, internally managed study of similar design*. In addition, the results of this study will help inform the design of a larger, efficacy focused, registrational MS protocol anticipated to begin by the end of the year.”

“We are proud of the significant progress that has been made in the clinical development and validation of this protocol. We are pleased with the smooth execution of the trial and we are looking forward to the data analyses, which we hope will reflect the hard work of both the clinical team and the subjects.” added Dr. Gabriel Leonard, Principal Investigator of the study.

* “Non-invasive neuromodulation to improve gait in chronic multiple sclerosis: a randomized double blind controlled pilot trial”: Journal of NeuroEngineering and Rehabilitation 2014, 11:79

About the PoNS(TM)

The Portable Neuromodulation Stimulator (PoNSTM) device is an investigational medical device being studied for the treatment of neurological symptoms caused by disease or trauma as part of a physical therapy program. The PoNSTM is currently being studied in the United States for the treatment of balance disorder for subjects with mild to moderate Traumatic Brain Injury (mTBI), and in Canada for the treatment of gait and balance disorder for subjects with Multiple Sclerosis (MS).

The PoNSTM device is believed to be the first non-invasive means for delivering neurostimulation through the tongue. Researchers believe that use of the tongue as a gateway to the brain may be one of the most natural, non-invasive and direct ways to stimulate the brain. The tongue is anatomically unique, being richly innervated by thousands of nerve fibers and interconnected to the brainstem by two major cranial nerves.

About Helius Medical Technologies (HMT)

Helius Medical Technologies is a medical technology company focused on neurological wellness. HMT seeks to use unique and non-invasive platform technologies that amplify the brain’s ability to heal itself. HMT intends to file for U.S. Food and Drug Administration clearance for the PoNS(TM) device. For more information, please visit www.heliusmedical.com.

About the Montreal Neurological Institute

The Montreal Neurological Institute and Hospital – (“The Neuro”) is a world-leading destination for brain research and advanced patient care. Since its founding in 1934 by renowned neurosurgeon Dr. Wilder Penfield, The Neuro has grown to be the largest specialized neuroscience research and clinical center in Canada, and one of the largest in the world. The seamless integration of research, patient care, and training of the world’s top minds make The Neuro uniquely positioned to have a significant impact on the understanding and treatment of nervous system disorders. The Montreal Neurological Institute is a McGill University research and teaching institute. The Montreal Neurological Hospital is part of the Neuroscience Mission of the McGill University Health Centre.

Cautionary Disclaimer Statement:

The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

This news release contains forward-looking statements relating to the completion of the listing of the Company’s shares on the Canadian Securities Exchange and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the Canadian Securities Exchange and other risks detailed from time to time in the filings made by the Company with securities regulations.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

# # #

Contact:

Investor Relations:
778-588-7144
info@heliusmedical.com

Corporate Contact:
Phil Deschamps
614-596-2597
pdeschamps@heliusmedical.com

Media Contact:
Becky Kern
914-772-2310
media@heliusmedical.com 

SOURCE: Helius Medical Technologies, Inc.

ReleaseID: 429082

VANCOUVER, BC / ACCESSWIRE / May 20, 2015 / Discovery Harbour Resources Corp (TSXV: DHR) (“DHR” or the “Company”) is pleased to announce that it has contracted a drilling program at its 100% owned 2BAR Project in Nevada.

This program has been designed to further test the continuity of the oxide copper mineralization occurring in outcrop and encountered during the Company’s drilling program in November, 2014. That program was fully described in a press release on January 26, 2015.

The program is modest at 1,500 to 2,000 feet and scheduled to begin on June 7th. The Company anticipates this program to last two to three weeks.

Drill site locations are presently being selected, based on geology from mapping, previous drilling and from the results of ground geophysics. The objective of this phase is to confirm that thicknesses and grades of copper that were encountered during the November program, continue under the younger Tertiary cover for distances up to 400 feet from drill holes 2B14-05, 2B14-06 and 2B14-07. Confirmation of this objective will indicate that lateral continuity of mineralization does exist at 2BAR.

Marcus & Marcus Drilling, based in Idaho, will be performing the operations for the Company. DHR Qualified Persons will be maintaining a secure chain-of-custody of all core and samples. These will ultimately be delivered to ALS Global in Reno, Nevada for analysis and storage.

Michael J. Senn, a licensed professional geologist, is the Qualified Person for Discovery Harbour Resources as described in National Instrument 43-101 and has reviewed and approved the technical contents of this release.

For further information, contact Kieran Magee by telephone at (778) 945-2958 or by email at Kieran@discoveryharbour.com.

ON BEHALF OF THE BOARD OF DISCOVERY HARBOUR RESOURCES CORP.

“Bruno Hegner“

Frank D. Hegner
President, CEO, and Director

Disclaimer for Forward-Looking Information

Certain information regarding the Company contained in this press release may constitute forward-looking statements within the meaning of applicable securities laws. Forward-looking statements may include estimates, plans, opinions, forecasts, projections or other statements that are not statements of fact.  Although the Company believes that expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct.  The Company cautions that actual performance will be affected by a number of factors, many of which are beyond the Company’s control, and that future events and results may vary substantially from what the Company currently foresees. 

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Discovery Harbour Resources Corp 

ReleaseID: 429081